CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Significant Increase in Short Interest

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 6,000 shares, a growth of 87.5% from the December 15th total of 3,200 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 14,500 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and issued a $14.00 target price on shares of CollPlant Biotechnologies in a report on Wednesday, November 27th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

Institutional Trading of CollPlant Biotechnologies

A hedge fund recently bought a new stake in CollPlant Biotechnologies stock. Benjamin Edwards Inc. acquired a new stake in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,810 shares of the company’s stock, valued at approximately $112,000. Benjamin Edwards Inc. owned about 0.21% of CollPlant Biotechnologies as of its most recent filing with the Securities and Exchange Commission. 21.69% of the stock is owned by institutional investors.

CollPlant Biotechnologies Price Performance

Shares of CLGN traded down $0.09 during midday trading on Tuesday, reaching $3.84. The stock had a trading volume of 1,354 shares, compared to its average volume of 6,282. The company has a market cap of $43.99 million, a price-to-earnings ratio of -2.49 and a beta of 0.63. The company’s fifty day simple moving average is $3.98 and its two-hundred day simple moving average is $4.47. CollPlant Biotechnologies has a 1-year low of $3.24 and a 1-year high of $6.75.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.